OMB Clears FDA’s Final Guidance On Clinical Research For Cannabis

The White House Office of Management and Budget has completed its review of FDA’s final guidance on clinical research for cannabis and cannabis-derived compounds, coming as the agency also reportedly plans to make recommendations for how to regulate cannabis-derived products, including those containing cannabidiol (CBD). The guidance cleared by OMB on Jan. 13, “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research,” is focused on development of cannabis-based drug products. It also discusses key regulatory concepts for stakeholders who may...